全文获取类型
收费全文 | 21750篇 |
免费 | 1429篇 |
国内免费 | 57篇 |
学科分类
医药卫生 | 23236篇 |
出版年
2024年 | 20篇 |
2023年 | 145篇 |
2022年 | 249篇 |
2021年 | 515篇 |
2020年 | 325篇 |
2019年 | 473篇 |
2018年 | 548篇 |
2017年 | 426篇 |
2016年 | 454篇 |
2015年 | 616篇 |
2014年 | 797篇 |
2013年 | 1032篇 |
2012年 | 1728篇 |
2011年 | 1731篇 |
2010年 | 987篇 |
2009年 | 924篇 |
2008年 | 1523篇 |
2007年 | 1668篇 |
2006年 | 1502篇 |
2005年 | 1495篇 |
2004年 | 1451篇 |
2003年 | 1369篇 |
2002年 | 1189篇 |
2001年 | 182篇 |
2000年 | 135篇 |
1999年 | 186篇 |
1998年 | 239篇 |
1997年 | 160篇 |
1996年 | 139篇 |
1995年 | 113篇 |
1994年 | 115篇 |
1993年 | 96篇 |
1992年 | 64篇 |
1991年 | 56篇 |
1990年 | 48篇 |
1989年 | 53篇 |
1988年 | 44篇 |
1987年 | 46篇 |
1986年 | 38篇 |
1985年 | 38篇 |
1984年 | 34篇 |
1983年 | 38篇 |
1982年 | 31篇 |
1981年 | 29篇 |
1980年 | 28篇 |
1979年 | 11篇 |
1978年 | 14篇 |
1977年 | 16篇 |
1976年 | 19篇 |
1970年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Conall T. Morgan Brigitte Mueller Varsha Thakur Vitor Guerra Callaghan Jull Luc Mertens Mark Friedberg Fraser Golding Mike Seed Steven E.S. Miner Edgar T. Jaeggi Cedric Manlhiot Lynne E. Nield 《The Canadian journal of cardiology》2019,35(4):453-461
Background
The purpose of the study was to evaluate the association between fetal echocardiographic measurements and the need for intervention (primary coarctation repair, staged coarctation repair, or catheter intervention) in prenatally diagnosed coarctation of the aorta.Methods
A single-centre retrospective cohort study (2005-2015) of 107 fetuses diagnosed with suspected coarctation of the aorta in the setting of an apex-forming left ventricle and antegrade flow across the mitral and aortic valves.Results
Median gestational age at diagnosis was 32 weeks (interquartile range, 23-35 weeks). Fifty-six (52%) did not require any neonatal intervention, 51 patients (48%) underwent a biventricular repair. In univariable analysis, an increase in ascending aorta (AAo) peak Doppler flow velocity (odds ratio [OR], 1.40 [95% confidence interval [CI], 1.05-1.91] per 20 cm/s; P = 0.03) was associated with intervention. No intervention was associated with larger isthmus size (OR, 0.23; P < 0.001), transverse arch diameter (OR, 0.23; P < 0.001), and aortic (OR, 0.72; P = 0.02), mitral (OR, 0.58; P = 0.001), and AAo (OR, 0.53; P < 0.001) z-scores. In multivariable analysis, higher peak AAo Doppler (OR, 2.51 [95% CI, 1.54-4.58] per 20 cm/s; P = 0.001) and younger gestational age at diagnosis (OR, 0.81 [95% CI, 0.70-0.93] per week; P = 0.005) were associated with intervention, whereas a higher AAo z-score (OR, 0.65 [95% CI, 0.43-0.94] per z; P = 0.029) and transverse arch dimension (OR, 0.44 [95% CI, 0.18-0.97]; P = 0.05) decreased the risk of intervention.Conclusions
In prenatally suspected coarctation, the variables associated with intervention comprised smaller AAo and transverse arch size, earlier gestational age at diagnosis, and the additional finding of a higher peak AAo Doppler. 相似文献2.
3.
ABSTRACTA monocausal bacteriological understanding of infectious disease orients tuberculosis control efforts towards antimicrobial interventions. A bias towards technological solutions can leave multistranded public health and social interventions largely neglected. In the context of globalising biomedical approaches to infectious disease control, this ethnography-inspired review article reflects upon the implementation of rapid diagnostic technology in low- and middle-income countries. Fieldwork observations in Vietnam provided a stimulus for a critical review of the global rollout of tuberculosis diagnostic technology. To address local needs in tuberculosis control, health managers in resource-poor settings are readily cooperating with international donors to deploy novel diagnostic technologies throughout national tuberculosis programme facilities. Increasing investment in new diagnostic technologies is predicated on the supposition that these interventions will ameliorate disease outcomes. However, suboptimal treatment control persists even when accurate diagnostic technologies are available, suggesting that promotion of singular technological solutions can distract from addressing systemic change, without which disease susceptibility, propagation of infection, detection gaps, diagnostic delays, and treatment shortfalls persist. 相似文献
4.
5.
6.
Measurements were made of glutathione (GSH) levels, catalase activity and the oxidant sensitivity of the erythrocytes from
the koala (Phascolarctos cinereus) and the common brushtail possum (Trichosurus vulpecula). The oxidant sensitivity was tested by treating the haemolysates with either 0.55 him H2O2 or 1.4mm NaNO2. The erythrocytes of the koala had greater levels of GSH and catalase and yet were found to be more susceptible to oxidation
induced by both these oxidants. 相似文献
7.
8.
Chris Giles 《Canadian Medical Association journal》2002,167(7):786-787
9.
10.
FDA’S Perspectives on Cardiovascular Devices 总被引:1,自引:0,他引:1
Eric A. Chen Sonna M. Patel-Raman Kathryn O’Callaghan Matthew G. Hillebrenner 《Journal of cardiovascular translational research》2009,2(2):143-146
The Food and Drug Administration (FDA) decision process for approving or clearing medical devices is often determined by a
review of robust clinical data and extensive preclinical testing of the device. The mission statement for the Center for Devices
and Radiological Health (CDRH) is to review the information provided by manufacturers so that it can promote and protect the
health of the public by ensuring the safety and effectiveness of medical devices deemed appropriate for human use (Food, Drug
& Cosmetic Act, §903(b)(1, 2(C)), December 31, 2004; accessed December 17, 2008 ). For high-risk devices, such as ventricular assist devices (VADs), mechanical heart valves, stents, cardiac resynchronization
therapy (CRT) devices, pacemakers, and defibrillators, the determination is based on FDA’s review of extensive preclinical
bench and animal testing followed by use of the device in a clinical trial in humans. These clinical trials allow the manufacturer
to evaluate a device in the intended use population. FDA reviews the data from the clinical trial to determine if the device
performed as predicted and the clinical benefits outweigh the risks. This article reviews the regulatory framework for different
marketing applications related to cardiovascular devices and describes the process of obtaining approval to study a cardiovascular
device in a U.S. clinical trial. 相似文献